KilgourMD, a scalp health and hair growth brand founded by board-certified dermatologist Dr. James Kilgour, has released promising results from a Phase II clinical trial focused on addressing hair loss in menopausal women. Announced on February 19, 2026, the independent study evaluated the KilgourMD System, which includes Prevention and Treatment Serums, in a cohort of 43 participants aged 45 to 65 experiencing androgenetic alopecia.
Historically, menopausal women have been underrepresented in hair loss research, often facing challenges that standard treatments do not adequately address. The trial aimed to fill this gap by requiring participants to exhibit a clinically significant level of hair loss, ensuring that the results accurately reflected therapeutic efficacy. Unlike many previous studies that relied on subjective consumer perceptions, this trial utilized objective measures evaluated by dermatologists.
The findings indicated that by day 120, 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, a key indicator of hair regrowth. Additionally, 26% of participants recorded a full one-grade improvement. These results are noteworthy as they compare favorably to improvements typically seen after six to twelve months of conventional treatments, such as minoxidil or finasteride.
Participants in the study experienced an average improvement of 11.1% in their Ludwig score within just four months. Alongside regrowth, there was a substantial reduction in hair shedding. By month four, assessments showed a 60% decrease in hair shedding, indicating a normalization of the hair growth cycle and improved follicular health.
Results highlighted that more than 95% of participants demonstrated a decrease in terminal hair shedding counts as early as day 45, based on standardized hair washing studies. These improvements were confirmed through evaluations by two independent board-certified dermatologists, alongside high-resolution imaging which revealed visible enhancements in hair density and scalp coverage.
Consumer-reported outcomes also supported the clinical data, with over 80% of participants noting significant improvements in hair density, health, and overall appearance by the study’s conclusion.
Dr. James Kilgour emphasized the importance of this research, stating, “Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning. This study validates not only the performance of the KilgourMD System but also the importance of designing and testing solutions specifically for this population.”
These clinical findings set a new standard for evidence-based solutions in the hair loss market, demonstrating that meaningful regrowth and reduced shedding can be achieved in a matter of months rather than years. The full results of the trial are currently undergoing peer review and are expected to be published later this year.
KilgourMD aims to revolutionize haircare by prioritizing scalp health. Founded by Dr. Kilgour, the brand was inspired by his mother’s struggles with menopause-related hair loss. KilgourMD employs advanced formulas and proprietary technologies to address scalp aging and improve hair thinning across all genders and hair types. By focusing on prevention as well as treatment, the brand promotes long-term scalp health and aims for fuller, stronger hair.
